Steve O’Loughlin
Chief Financial OfficerMr. Steve O’Loughlin, MBA, is Chief Financial Officer of CNS Pharmaceuticals, Inc. from March 2, 2026. Mr. O’Loughlin served as Chief Financial Officer of Actinium Pharmaceuticals, Inc. from August 2020 until February 2026 and as its Principal Financial Officer from May 2017 to August 2020. Mr. O’Loughlin joined Actinium Pharmaceuticals, Inc. in October 2015 as Vice President, Finance and Corporate Development. From June 2015 to October 2015, Mr. O’Loughlin worked at J. Streicher LLC as an investment banker, from August 2012 to June 2015 Mr. O’Loughlin held the position of vice president, corporate finance and development and was a corporate officer at Protea Biosciences, Inc., a publicly traded life sciences tools company. Previously, From June 2010 to June 2012, Mr. O’Loughlin held corporate development positions with Caliber I.D., a publicly traded diagnostics company. Mr. O’Loughlin previously worked in investment banking at Jesup & Lamont where he focused on the biotechnology and life sciences industries. Mr. O’Loughlin has a B.S. in Business Administration with a concentration in finance from Ramapo College of New Jersey.
Positions
- Company NameCNS Pharmaceuticals, Inc.Stock CodeCNSPPositionChief Financial OfficerColleagues
- RLRami LevinPresident, CEO & Director
- FLFaith L. CharlesIndependent Chairman of Board
- EFEric FaulknerChief Technology Officer
- DWDylan WenkeChief Business Officer
- ELE. Lynne KelleyChief Medical Officer
- JRJeffry R. KeyesIndependent Director
- BMBettina M. CockroftIndependent Director
- AMAmy MaheryIndependent Director
